{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:17:52Z","timestamp":1760782672468},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[1991,1,1]],"date-time":"1991-01-01T00:00:00Z","timestamp":662688000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[1991]]},"DOI":"10.1007\/bf00626371","type":"journal-article","created":{"date-parts":[[2004,11,26]],"date-time":"2004-11-26T05:14:48Z","timestamp":1101446088000},"page":"467-470","source":"Crossref","is-referenced-by-count":46,"title":["Debrisoquine oxidation phenotype during neuroleptic monotherapy"],"prefix":"10.1007","volume":"41","author":[{"given":"E.","family":"Spina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Martines","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. P.","family":"Caputi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Cobaleda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Pi\ufffdas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Carrillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Benitez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0140-6736(77)91430-1","volume":"II","author":"A Mahgoub","year":"1977","unstructured":"Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet II: 584?586","journal-title":"Lancet"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF00562059","volume":"16","author":"M Eichelbaum","year":"1979","unstructured":"Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16: 183?187","journal-title":"Eur J Clin Pharmacol"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.1840060534","volume":"6","author":"E Jacqz","year":"1986","unstructured":"Jacqz E, Hall SD, Branch RA (1986) Genetically determined polymorphisms in drug oxidation. Hepatology 6: 1020?1032","journal-title":"Hepatology"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2165\/00003088-199018030-00004","volume":"18","author":"K Brosen","year":"1990","unstructured":"Brosen K (1990) Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics. Clin Pharmacokinet 18: 220?239","journal-title":"Clin Pharmacokinet"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/dna.1.1989.8.1","volume":"8","author":"DW Nebert","year":"1989","unstructured":"Nebert DW, Nelson DR, Adesnik M, Coon MJ, Estabrook RW, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF, Kemper B, Levin W, Phillips IR, Sato R, Waterman MR (1989) The P450 superfamily: updated listing of all genes and recommendeed nomenclature for the chromosomal loci. DNA 8: 1?13","journal-title":"DNA"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/BF00637732","volume":"36","author":"K Brosen","year":"1989","unstructured":"Brosen K, Gram LF (1989) Clinical significance of the sparteine\/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 36: 537?547","journal-title":"Eur J Clin Pharmacol"},{"key":"CR7","first-page":"377","volume":"46","author":"M Eichelbaum","year":"1990","unstructured":"Eichelbaum M, Gross AS (1990) The genetic polymorphism of debrisoquine\/sparteine metabolism. Clinical aspects. Pharmacol Ther 46: 377?394","journal-title":"Clinical aspects. Pharmacol Ther"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/clpt.1985.193","volume":"38","author":"E Steiner","year":"1985","unstructured":"Steiner E, Iselius L, Alvan G, Lindsten J, Sj\u00f6qvist F (1985) A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther 38: 394?401","journal-title":"Clin Pharmacol Ther"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2125.1986.tb02969.x","volume":"22","author":"CJ Speirs","year":"1986","unstructured":"Speirs CJ, Murray S, Boobis AR, Seddon CE, Davies DS (1986) Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Br J Clin Pharmacol 22: 739?743","journal-title":"Br J Clin Pharmacol"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1600-0773.1987.tb01758.x","volume":"60","author":"K Brosen","year":"1987","unstructured":"Brosen K, Gram LF, Haghfelt T, Bertilsson L (1987) Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol 60: 312?314","journal-title":"Pharmacol Toxicol"},{"key":"CR11","first-page":"443","volume":"13","author":"T Inaba","year":"1985","unstructured":"Inaba T, Jurima A, Mahon WA, Kalow W (1985) In vitro inhibition studies of two isozymes of human liver cytochrome P-450: mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos 13: 443?448","journal-title":"Drug Metab Dispos"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1016\/0006-2952(85)90533-7","volume":"34","author":"C Bahr von","year":"1985","unstructured":"von Bahr C, Spina E, Birgersson C, Ericsson O, Goransson M, Henthorn T, Sj\u00f6qvist F (1985) Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem Pharmacol 34: 2501?2505","journal-title":"Biochem Pharmacol"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1016\/0006-2952(88)90063-9","volume":"37","author":"R Fonne-Pfister","year":"1988","unstructured":"Fonne-Pfister R, Meyer UA (1988) Xenobiotic and endobiotic inhibitors of cytochrome P-450db1 function, the target of the debrisoquine\/sparteine type polymorphism. Biochem Pharmacol 37: 3829?3835","journal-title":"Biochem Pharmacol"},{"key":"CR14","first-page":"89","volume":"22","author":"EKG Syvalahti","year":"1986","unstructured":"Syvalahti EKG, Lindberg R, Kallio J, de Vocht M (1986) Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol 22: 89?92","journal-title":"Br J Clin Pharmacol"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF00561023","volume":"36","author":"F Derenne","year":"1989","unstructured":"Derenne F, Joanne C, Vandel S, Bertschy G, Volmat R, Bechtel P (1989) Debrisoquine oxidative phenotyping and psychiatric drug treatment. Eur J Clin Pharmacol 36: 53?58","journal-title":"Eur J Clin Pharmacol"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/978-3-642-74430-3_22","volume-title":"Clinical pharmacology in psychiatry: from molecular studies to clinical reality","author":"J Benitez","year":"1989","unstructured":"Benitez J, Pi\u00f1as B, Garcia MA, Martinez C, Llerena A, Cobaleda J (1989) Debrisoquine oxidation phenotype in psychiatric patients. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry: from molecular studies to clinical reality. Springer, Berlin Heidelberg New York, pp 206?210"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/00007691-198911000-00019","volume":"11","author":"E Spina","year":"1989","unstructured":"Spina E, Buemi AL, Sanz E, Bertilsson L (1989) Diazepam treatment does not influence the debrisoquine or mephenytoin hydroxylation phenotyping tests. Ther Drug Monit 11: 721?723","journal-title":"Ther Drug Monit"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0021-9673(00)89216-X","volume":"133","author":"MS Lennard","year":"1977","unstructured":"Lennard MS, Silas JH, Smith AJ, Tucker GT (1977) Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame ionization and nitrogen selective detection. J Chromatogr 133: 161?166","journal-title":"J Chromatogr"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/jmg.17.2.102","volume":"17","author":"DA Evans","year":"1980","unstructured":"Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquin oxidation in a white British population. J Med Genet 17: 102?105","journal-title":"J Med Genet"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1365-2125.1985.tb02723.x","volume":"19","author":"C Nordin","year":"1985","unstructured":"Nordin C, Siwers B, Benitez J, Bertilsson L (1985) Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients ? relationship to the debrisoquin hydroxylation metabolic ratio. Br J Clin Pharmacol 19: 832?835","journal-title":"Br J Clin Pharmacol"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1365-2125.1989.tb05362.x","volume":"27","author":"LF Gram","year":"1989","unstructured":"Gram LF, Debruyne D, Caillard V, Boulanger JP, Lacotte J, Moulin M, Zarifian E (1989) Substantial rise in sparteine metabolic ratio during haloperidol treatment. Br J Clin Pharmacol 27: 272?275","journal-title":"Br J Clin Pharmacol"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1365-2125.1990.tb03827.x","volume":"30","author":"J Kallio","year":"1990","unstructured":"Kallio J, Huupponen R, Seppala M, Sako E, Iisalo E (1990) The effects of ?-adrenoceptor antagonists and levomepromazine on the metabolic ratio of debrisoquine. Br J Clin Pharmacol 30: 638?643","journal-title":"Br J Clin Pharmacol"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00870989","volume":"31","author":"G Mikus","year":"1986","unstructured":"Mikus G, Ha HR, Vozeh S, Zekorn C, Follath F, Eichelbaum M (1986) Pharmacokinetics and metabolism of quinidine in extensive and poor metabolizers of sparteine. Eur J Clin Pharmacol 31: 69?72","journal-title":"Eur J Clin Pharmacol"},{"key":"CR24","first-page":"111","volume":"9","author":"A Jorgensen","year":"1986","unstructured":"Jorgensen A (1986) Metabolism and pharmacokinetics of antipsychotic drugs. Progr Drug Metab 9: 111?174","journal-title":"Progr Drug Metab"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/00003088-198713020-00001","volume":"13","author":"AE Balant-Gorgia","year":"1987","unstructured":"Balant-Gorgia AE, Balant L (1987) Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring. Clin Pharmacokinet 13: 65?90","journal-title":"Clin Pharmacokinet"},{"key":"CR26","first-page":"163","volume-title":"Clinical pharmacology in psychiatry: from molecular studies to clinical reality","author":"C Bahr von","year":"1989","unstructured":"von Bahr C, Guengerich FP, Morin G, Nordin C (1989) The use of human liver banks in pharmacogenetic research. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry: from molecular studies to clinical reality. Springer, Berlin Heidelberg New York, pp 163?171"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/clpt.1989.109","volume":"46","author":"ML Dahl-Puustinen","year":"1989","unstructured":"Dahl-Puustinen ML, Liden A, Alm C, Bertilsson L (1989) Disposition of perphenazine is related to the polymorphic debrisoquine hydroxylation in man. Clin Pharmacol Ther 46: 78?81","journal-title":"Clin Pharmacol Ther"},{"key":"CR28","first-page":"165","volume":"1","author":"LF Gram","year":"1972","unstructured":"Gram LF, Fredricson Overo K (1972) Drug interaction: inhibitory effect of neuroleptics on the metabolism of tricyclic antidepressants in man. Br Med J 1: 165?175","journal-title":"Br Med J"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/BF00316090","volume":"39","author":"G Alvan","year":"1990","unstructured":"Alvan G, Bechtel P, Iselius L, Gundertremy U (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39: 533?538","journal-title":"Eur J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00626371.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00626371\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00626371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T19:07:44Z","timestamp":1554836864000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00626371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1991]]}},"alternative-id":["BF00626371"],"URL":"https:\/\/doi.org\/10.1007\/bf00626371","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991]]}}}